Optimal MRI Protocol for Prostate and Bladder Evaluation
For simultaneous evaluation of both prostate and bladder, order a multiparametric MRI pelvis with and without IV contrast at 1.5T or 3T (preferably 3T) using a pelvic phased-array surface coil, including T2-weighted imaging, diffusion-weighted imaging (DWI) with ADC maps, and dynamic contrast-enhanced (DCE) imaging. 1, 2
Core Technical Specifications
Field Strength and Coil Selection
- Use 1.5T or 3T MRI scanner, with 3T preferred for improved signal-to-noise ratio and superior spatial resolution 2
- Employ a pelvic phased-array surface coil positioned over the pelvis—an endorectal coil is neither mandatory nor routinely recommended at either field strength 2
- 3T systems provide comparable performance to 1.5T with endorectal coil when using multichannel phased-array coils 1
Required Imaging Sequences
All three sequences below are mandatory and must be included:
T2-weighted imaging (axial, sagittal, and coronal planes):
- Provides anatomic detail of prostate zones, seminal vesicles, ejaculatory ducts, and bladder wall layers 1, 2
- Critical for assessing depth of bladder wall invasion and distinguishing superficial from deep muscle invasion 1
- Superior to CT for detecting invasion of detrusor muscle and perivesical tissues 1
Diffusion-weighted imaging (DWI) with ADC mapping:
- Use high b-values (b=1400-2000) for optimal cancer detection 2
- Detects areas of restricted diffusion correlating with tumor cellularity 2, 3
- Improves accuracy in distinguishing muscle-invasive from non-muscle-invasive bladder cancer (sensitivity 78-98%, specificity 82-100%) 1
- Enhances detection of malignant lymph nodes (sensitivity 61-94%, specificity 90-99%) 1
Dynamic contrast-enhanced (DCE) imaging with IV gadolinium:
Multiparametric Approach: The Gold Standard
Multiparametric MRI combining T2-weighted imaging, DWI, and DCE is the most optimal technique for local staging of both bladder and prostate pathology. 1
- This combined approach achieves sensitivity 90-94% and specificity 60-94% for distinguishing organ-confined from non-organ-confined bladder tumors 1
- For bladder cancer, use the VI-RADS (Vesical Imaging-Reporting and Data System) 5-point scoring system to estimate likelihood of detrusor muscle invasion 1
- For prostate evaluation, follow PI-RADS version 2.1 standards 2
Field of View Considerations
- Small field-of-view images: High-resolution axial T1-weighted and multiplanar T2-weighted sequences for detailed prostate gland, seminal vesicles, ejaculatory ducts, and bladder wall evaluation 1
- Large field-of-view images: Extended coverage to assess pelvic lymphadenopathy and extravesical disease 1
Critical Timing and Clinical Context
Timing Considerations
- Perform MRI at least 6 weeks after prostate biopsy to avoid hemorrhage artifact that degrades image quality 2
- If evaluating post-focal therapy, obtain first MRI at 12 months after treatment to minimize treatment-induced artifacts 2
Essential Clinical Information to Provide
When ordering, include: 2
- Recent PSA values
- Gleason scores from any prior biopsies
- Details of any prior focal therapy or bladder procedures
- Specific indication for the study
Common Pitfalls to Avoid
- Never accept incomplete protocols: If any required sequence is missing or of inadequate quality, repeat before making treatment decisions 2
- Do not order MRI without contrast for bladder evaluation: Non-contrast protocols have insufficient accuracy for local staging 1
- Ensure adequate radiologist experience: The interpreting radiologist should read at least 20 prostate MRI examinations annually 2
- Always obtain comparison images: Essential for detecting interval changes, particularly in surveillance scenarios 2
Alternative Considerations
- MR urography (MRU) with and without contrast can be added if upper tract evaluation is needed, providing superior contrast resolution compared to CT urography for small tumor detection 1
- PSMA PET/CT may be considered as an adjunct in specific scenarios (high-risk disease, biochemical recurrence), though data for routine use remain limited 1